Jornal Brasileiro de Psiquiatria
January 1, 2024
Dráulio Barros de Araújo, Tiago Arruda Sanchez, Sidarta Ribeiro
1 citation
Psychedelic substances have been used by humanity for millennia to induce non-ordinary states of consciousness, characterized by heightened sensory, emotional, and cognitive experiences, including augmented visual imagery, altered perception of space-time and reality, and profound mystical insights. Many indigenous populations worldwide developed these substances as vital components of healing. In the Amazon, shamans ancestrally used Ayahuasca, a drink made from two plants, to promote physical and psychological healing. The Navajo in North America retain the ancestral use of the peyote cactus as sacred medicine, while the Mazatecs of Mexico used psilocybin-containing mushrooms in their healing rituals.
Journal of Psychedelic Studies
June 9, 2023
Beatriz Caiuby Labate, Anna O. Ermakova, Jordan Sloshower et al.
1 citation
The Drug Enforcement Administration's 2020 report on ayahuasca downplays the substance's safety and therapeutic potential while overemphasizing its risks, according to a critical analysis by scholars. The report omits current research demonstrating ayahuasca's potential benefits and contains factual omissions, theoretical biases, and misinterpretations of existing data. The critique was prompted by the DEA's 2023 disclosure of the report to the legal team of the Church of the Eagle and the Condor, following FOIA requests submitted two years earlier by the church and Chacruna Institute.
Journal of Psychopharmacology
July 8, 2026
Raynara Bolcont, Fernanda Palhano-Fontes, Handersson Barros et al.
Inhaled DMT, combined with psychological support, is associated with reduced state anxiety up to one day after administration in both healthy individuals and patients with treatment-resistant depression. Healthy volunteers reported increased life satisfaction up to 14 days. Patients showed increased life satisfaction after 12 months and sustained improvements in quality of life over that period, including physical health, psychological health, social relationships, and environment, as well as inner peace and hope and optimism. The study is limited by an open-label design, lack of placebo control, and modest sample size.
bioRxiv (Cold Spring Harbor Laboratory)
December 11, 2025
Caroline L. Alves, Fernanda Palhano-Fontes, Thaise G. L. de O. Toutain et al.
Ayahuasca alters conscious experience, and this study identifies EEG markers of its network-level effects using machine learning and complex-network analysis. In a randomized, double-blind, placebo-controlled trial with naïve ayahuasca users, resting-state EEG was recorded before dosing, 2 hours after, and 4 hours after. Connectivity was estimated with sliding windows; optimal classification performance occurred at 60–70 seconds (AUC and accuracy = 0.93). Network analysis revealed a bilateral decrease in eigenvector centrality (weaker hub influence), increased degree heterogeneity in the right hemisphere, and reduced global efficiency in the left. Posterior-left connections weakened acutely, while right temporal–central coupling transiently strengthened. The findings suggest that hub-centric shortcuts weaken, routing communication through more distributed, less efficient pathways with right-lateralized expression.
Journal of Psychopharmacology
December 4, 2025
Natan Silva-Costa, Jéssica Andrade Pessoa, Kátia Cristina Andrade et al.
Ayahuasca produces profound changes in perception, cognition, and emotion, including mystical experiences and altered mind-wandering, while decreasing global alpha brain oscillations and increasing frontomedial delta and right posterior theta and beta. Lower theta during the experience is linked to stronger mystical experiences, and higher alpha is associated with less thought about nothing. Baseline brain activity before taking ayahuasca can predict some subjective effects: lower baseline theta predicts stronger bodily awareness and interoception, and lower baseline beta predicts greater positive emotionality.
Ponto Urbe
December 27, 2024
Beatriz Caiuby Labate, Anna O. Ermakova, Jordan Sloshower et al.
In February 2023, the U.S. Drug Enforcement Administration (DEA) released a 2020 report titled 'Ayahuasca: Risks to Public Health and Safety' to the legal team of the Church of the Eagle and the Condor, following Freedom of Information Act requests. This article challenges several claims in the DEA report, highlighting factual omissions, theoretical biases, and misinterpretations of existing data. The authors argue that the report minimizes ayahuasca's safety profile and therapeutic potential while overemphasizing risks, and fails to include current research demonstrating its potential benefits.
bioRxiv (Cold Spring Harbor Laboratory)
February 13, 2017
Vanja Dakic, Juliana Nascimento, Rafaela Sartore et al.
preprint
5-MeO-DMT, a hallucinogenic molecule found in traditional Amerindian medicine, alters the proteome of human cerebral organoids. Of 6,728 identified proteins, 934 were differentially expressed after treatment. Systems biology analyses indicate anti-inflammatory effects and modulation of proteins linked to long-term potentiation, dendritic spine formation, cellular protrusion, microtubule dynamics, and cytoskeletal reorganization. These findings provide mechanistic insights into the neuropsychological changes associated with dimethyltryptamine ingestion.